Phobos Environment Model and Regolith Simulant for MMX Mission

Phobos and Deimos, the two moons of Mars, are considered to be scientifically important and potential human mission's target. Martian Moons eXplorer (MMX) is the JAXA's mission to explore Phobos (and/or Deimos), which is scheduled to be launched in 2024. The main spacecraft of MMX will perform in-situ observations of both Phobos and Deimos, land on one of them (most likely, Phobos), and bring samples back to Earth. Small landing modules may be included in the mission as for the Hayabusa-2 mission. The designs of both the landing and sampling devices depend largely on the surface conditions of the target body and on how this surface reacts to an external action in the low gravity conditions of the target. Thus, the Landing Operation Working Team (LOWT) of MMX, which is composed of both scientists and engineers, is studying Phobos' surface based on previous observations and theoretical/experimental considerations. Though engineering motivation initiated this activity, the results will be extremely useful for scientific purposes

Concomitant right subscapular and left olecranon elastofibroma followed by inversion of the lesions: Case report

Elastofibroma is a benign, poorly circumscribed, tumor-like condition involving, in the vast majority of cases, the subscapular region of elderly individuals, though isolated cases have been seen in the deltoid muscle, infraolecranon area, hip, thigh and stomach. It is characterized by accumulated abnormal elastic fibres and is generally regarded as a reactive process, an unusual fibroblastic pseudotumor. Multiple elastofibromas have been reported to occur in the scapula and olecranon and in the scapula and ischium, whereas literature reports of multiple elastofibromas in the same patient are rare. The case of concomitant, asynchronous double elastofibroma in the same patient is described. A 69-year-old woman presented with right subscapular and left olecranon swelling associated with pain and a clicking sensation during certain arm movements. Some months later the patient developed asymptomatic left subscapular and right olecranon swelling. All the lesions, which were subsequentely disgnosed as elastofibromas, were removed

Midazolam dose correlates with abnormal hippocampal growth and neurodevelopmental outcome in preterm infants.

OBJECTIVE: Very preterm-born neonates (24-32 weeks of gestation) are exposed to stressful and painful procedures during neonatal intensive care. Analgesic and sedation therapies are essential, and opiates and benzodiazepines are commonly used. These medications may negatively impact brain development. The hippocampus may be especially vulnerable to the effects of pain and analgesic and/or sedative therapies and contribute to adverse outcomes. The effect of invasive procedures and analgesic-sedative exposure on hippocampal growth was assessed, as was that of hippocampal growth on neurodevelopmental outcome. METHODS: A total of 138 neonates (51% male, median gestational age = 27.7 weeks) underwent magnetic resonance imaging and diffusion tensor imaging (DTI) scans, early in life (postmenstrual age [PMA] = 32.3 weeks) and at term-equivalent age (PMA = 40.2 weeks). Volumes and DTI measures of axial diffusivity, radial diffusivity, and mean diffusivity (MD) were obtained from the hippocampus. Cognitive, language, and motor abilities were assessed using the Bayley Scales of Infant Development-III at 18.7 months median corrected age. Models testing the association of invasive procedures with hippocampal volumes and DTI measures accounted for birth gestational age, sex, PMA, dose of analgesics/sedatives (fentanyl, morphine, midazolam), mechanical ventilation, hypotension, and surgeries. RESULTS: Total midazolam dose predicted decreased hippocampal volumes (β = -1.8, p \u3c 0.001) and increased MD (β = 0.002, p = 0.02), whereas invasive procedures did not (β = 0, p \u3e 0.5 each). Lower cognitive scores were associated with hippocampal growth (β = -0.31, p = 0.003), midazolam dose (β = -0.27, p = 0.03), and surgery (β = -8.32, p = 0.04). INTERPRETATION: Midazolam exposure was associated with macro- and microstructural alterations in hippocampal development and poorer outcomes consistent with hippocampal dysmaturation. Use of midazolam in preterm neonates, particularly those not undergoing surgery, is cautioned

Primary esophageal and gastro-esophageal junction cancer xenograft models:Clinicopathological features and engraftment

<p><b>A–C.</b> Voltage recordings of locomotor-related drive obtained from embryonic slow (ES) fibres of control (<b>A</b>), DETA-NO raised (<b>B</b>) and L-NAME raised (<b>C</b>) fish at 2 days post fertilisation (dpf). <b>D–F</b>. Mean end plate potential (EPP) amplitude (<b>D</b>), rise time (<b>E</b>) and decay time (<b>F</b>) measured during episodes of fictive swimming. Data in <b>D-F</b> are represented as mean ± SEM. *** p<0.001.</p

Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers.

The high morbidity and mortality of patients with esophageal (E) and gastro-esophageal junction (GEJ) cancers, warrants new pre-clinical models for drug testing. The utility of primary tumor xenografts (PTXGs) as pre-clinical models was assessed. Clinicopathological, immunohistochemical markers (p53, p16, Ki-67, Her-2/neu and EGFR), and global mRNA abundance profiles were evaluated to determine selection biases of samples implanted or engrafted, compared with the underlying population. Nine primary E/GEJ adenocarcinoma xenograft lines were further characterized for the spectrum and stability of gene/protein expression over passages. Seven primary esophageal adenocarcinoma xenograft lines were treated with individual or combination chemotherapy. Tumors that were implanted (n=55) in NOD/SCID mice had features suggestive of more aggressive biology than tumors that were never implanted (n=32). Of those implanted, 21/55 engrafted; engraftment was associated with poorly differentiated tumors (p=0.04) and older patients (p=0.01). Expression of immunohistochemical markers were similar between patient sample and corresponding xenograft. mRNA differences observed between patient tumors and first passage xenografts were largely due to loss of human stroma in xenografts. mRNA patterns of early vs late passage xenografts and of small vs large tumors of the same passage were similar. Complete resistance was present in 2/7 xenografts while the remaining tumors showed varying degrees of sensitivity, that remained constant across passages. Because of their ability to recapitulate primary tumor characteristics during engraftment and across serial passaging, PTXGs can be useful clinical systems for assessment of drug sensitivity of human E/GEJ cancers

Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers

The high morbidity and mortality of patients with esophageal (E) and gastro-esophageal junction (GEJ) cancers, warrants new pre-clinical models for drug testing. The utility of primary tumor xenografts (PTXGs) as pre-clinical models was assessed. Clinicopathological, immunohistochemical markers (p53, p16, Ki-67, Her-2/neu and EGFR), and global mRNA abundance profiles were evaluated to determine selection biases of samples implanted or engrafted, compared with the underlying population. Nine primary E/GEJ adenocarcinoma xenograft lines were further characterized for the spectrum and stability of gene/protein expression over passages. Seven primary esophageal adenocarcinoma xenograft lines were treated with individual or combination chemotherapy. Tumors that were implanted (n=55) in NOD/SCID mice had features suggestive of more aggressive biology than tumors that were never implanted (n=32). Of those implanted, 21/55 engrafted; engraftment was associated with poorly differentiated tumors (p=0.04) and older patients (p=0.01). Expression of immunohistochemical markers were similar between patient sample and corresponding xenograft. mRNA differences observed between patient tumors and first passage xenografts were largely due to loss of human stroma in xenografts. mRNA patterns of early vs late passage xenografts and of small vs large tumors of the same passage were similar. Complete resistance was present in 2/7 xenografts while the remaining tumors showed varying degrees of sensitivity, that remained constant across passages. Because of their ability to recapitulate primary tumor characteristics during engraftment and across serial passaging, PTXGs can be useful clinical systems for assessment of drug sensitivity of human E/GEJ cancers